Trial Profile
Soluble CD23 expression as a marker of immunomodulation and clinical response in asthma patients treated with omalizumab
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 26 Nov 2005 New trial record.